-

Invetx Completes Development of Canine and Feline Half-Life Extension Technology Platform that Significantly Extends Duration of Monoclonal Antibody Treatment Effect

Long-Acting Therapeutics Make Chronic Diseases More Manageable and Provide Better Value for Pet Owners

BOSTON--(BUSINESS WIRE)--Invetx, a pioneer in protein-based therapeutics for animal health, announced that it has recently completed development of its species-specific, half-life extension technology for dogs and cats which leads to superior extended duration of activity for the company’s veterinary monoclonal antibodies. The novel technology enables the company to optimize antibody drug treatment options for chronic, serious diseases in dogs and cats. Invetx has been granted four patents in the U.S. related to its half-life extension technology, and has multiple patents pending in the U.S., Europe and other jurisdictions.

“We successfully completed an extensive engineering program to identify and validate novel, species-specific Fc variants and combinations of variants, which have FcRn binding affinities that improve the serum half-lives of antibodies. Our selected variants deliver significantly longer duration of drug activity in dogs and cats compared to those using standard human half-life extension technology,” said Bill Brondyk, PhD, chief scientific officer, Invetx. “The technology has been applied to all our product candidates and we have demonstrated its superior effect in the target species.”

“By lengthening the time between doses – to every other month, quarterly or possibly even longer – Invetx is making the treatment of chronic diseases more manageable and convenient for pet owners,” said Juergen Horn, Dr.med.vet., PhD, chief executive officer, Invetx. “We believe that continuous, professionally administered treatment with our novel therapeutics, combined with regular check-ups in the clinic, can lead to better health outcomes for pets, reduce cost of treatment and provide greater value to owners.”

The half-life extension technology is part of Invetx’s overall integrated platform, which includes best-in-class antibody discovery, optimization, development and manufacturing for veterinary biotherapeutics. The company is advancing a pipeline of novel antibody therapeutics for multiple diseases in cats and dogs.

About Invetx

Invetx has raised $86 million since 2018, including investors F-Prime Capital, Novo Holdings, GV, Eight Roads, Anterra Capital, Casdin Capital and funds managed by Tekla Capital Management, LLC. The company has strategic partnerships with Boehringer Ingelheim, a global leader in animal health, AbCellera, a global technology company specializing in antibody discovery located in Vancouver, BC, and WuXi Biologics, a global company with leading biologics technology platforms. Invetx is a private company headquartered in Boston, Massachusetts. For more information, see www.invetx.com.

Contacts

Invetx Partners and Investors:
Juergen Horn, Dr.med.vet, PhD
Chief Executive Officer
juergen.horn@invetx.com

Invetx Media:
Susan Kinkead
susan@kinkeadcomm.com
415-509-3610

Invetx


Release Versions

Contacts

Invetx Partners and Investors:
Juergen Horn, Dr.med.vet, PhD
Chief Executive Officer
juergen.horn@invetx.com

Invetx Media:
Susan Kinkead
susan@kinkeadcomm.com
415-509-3610

Social Media Profiles
More News From Invetx

Invetx Announces Upcoming Acquisition by Dechra Pharmaceuticals, Global Leader in Animal Health

BOSTON--(BUSINESS WIRE)--Invetx Inc., a pioneer in protein-based therapeutics for animal health, announced today that it has agreed to be acquired by Dechra Pharmaceuticals Limited (Dechra), a global specialist veterinary pharmaceuticals business, for up to $520 million in total consideration on a cash-free and debt-free basis. The acquisition remains subject to antitrust approval and other customary closing conditions. “We are thrilled to be joining forces with Dechra Pharmaceuticals, a global...

Invetx’s Market Research Study Reveals Nearly 40% of Dogs in the U.S. Suffer from Chronic Osteoarthritis/Pain

BOSTON--(BUSINESS WIRE)--Invetx, a pioneer in protein-based therapeutics for animal health, announced results of a market research study showing that both veterinarians and pet owners would switch to a longer-acting (and higher-priced) therapeutic to treat pain associated with chronic osteoarthritis in their pets. Invetx is developing a portfolio of monoclonal antibody (mAb) therapeutics to treat chronic conditions in cats and dogs by leveraging its patented half-life extension technology platf...

Invetx Appoints Dr. Marcus Remmers, Novo Holdings Partner and Animal Health Industry Leader, to Board of Directors

BOSTON--(BUSINESS WIRE)--Invetx, a pioneer in protein-based therapeutics for animal health, today announced the appointment of Dr. Marcus Remmers to its board of directors. “We are pleased to welcome Dr. Remmers, an accomplished life sciences executive with significant veterinary biologics and animal health expertise, to our board of directors,” said Juergen Horn, PhD, chief executive officer, Invetx. “He will be a valuable addition as we advance our pipeline of novel antibody therapeutics targ...
Back to Newsroom